single infusion of Rituximab

Phase 1Monoclonal antibody

AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab is one of 49 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nephrotic SyndromeActive, not recruiting

Venous MalformationActive, not recruiting

Nephrotic SyndromePhase 2/Phase 3

Active, not recruiting

Venous MalformationPhase 1

Active, not recruiting

Competition

Competitive Landscape

74 competitors in Nephrotic Syndrome

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

2 2

Rituxan

Roche

Phase 3

15 3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Cellcept

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 6

Trental

VValidus Pharmaceuticals

Phase 3

1 7

Midamor

PPadagis LLC

Phase 3

1 8

Jardiance

Boehringer Ingelheim

Phase 3

1 9

Eliquis

Bristol-Myers Squibb

Phase 2

3 10

Praluent

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Nephrotic Syndrome

NCT05786768

Q4 2028

Phase 1Not yet recruiting

Venous Malformation

NCT07075757

Clinical

Trials by Indication[1]

Nephrotic Syndrome1 trial

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT05786768·88 enrolled

Venous malformation1 trial

In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07075757·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for single infusion of Rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — single infusion of Rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for single infusion of Rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: AAssistance Publique - Hôpitaux de Paris

single infusion of Rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Nephrotic Syndrome1 trial

Venous malformation1 trial

References

Drug Info

Quick Facts

Related News